Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition, provides a comprehensive overview of the molecular methodologies in the neuro-oncology field. There have been profound changes in the landscape of approaches to brain tumor therapy since the first edition-mainly in the areas of molecular biology and molecular therapeutics, as well as in the maturation of immunotherapy approaches (e.g., vaccines). This updated edition has a new, primary focus on multidisciplinary molecular methods, and is broadened to include the latest cutting-edge molecular biology, therapeutics, immunobiology and immunotherapy approaches.
As the first comprehensive book to address the molecular research into these concepts, users will find it to be an invaluable resource on the topics discussed.
- Provides the most up-to-date information regarding conventional forms of cytotoxic chemotherapy, as well as the basic science and clinical application of molecular therapeutics for the treatment of brain tumors
- Broadly appeals to anyone interested in neuro-oncology and the treatment of brain tumors
- Features updated chapters on molecular biology, molecular therapeutics, maturation of immunotherapy approaches, and a focus on multidisciplinary molecular methods
- Includes a new section on the basic science of immunology, as well as thorough updates on the use of vaccine technology and immunotherapy for the treatment of brain tumors
SECTION I. PHARMACOLOGICAL AND CLINICAL APPLICATIONS 1. Overview of Brain Tumor Epidemiology and Histopathology 2. Clinical Pharmacology of Brain Tumor Chemotherapy 3. Antiepileptic drugs and chemotherapy: Potential interactions and impact on treatment of patients with cancer 4. Brain Tumor Models for Cancer Therapy 5. Genomics and proteomics in neuro-oncology 6. Chemotherapy Resistance 7. Clinical Trial Design and Implementation in Neuro-Oncology 8. Biology of the Blood-Brain and Blood-Brain Tumor Barriers
SECTION II. INNOVATIVE CHEMOTHERAPY DELIVERY 9. Intra-arterial Chemotherapy 10. Blood-Brain Barrier Disruption Chemotherapy 11. Interstitial Chemotherapy and Polymer-Drug Delivery 12. Intratumoral Chemotherapy and Convection-Enhanced Delivery 13. Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue in Brain Tumors 14. CSF Dissemination of Primary Brain Tumors 15. Gene/Viral Treatment Approaches for Malignant Brain Cancer 16. Nanoparticles as Therapeutic Agents for Brain Tumors
SECTION III. MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS 17. Overview of Molecular Genetics of Brain Tumors 18. Cell Cycle Regulation 19. Targeting cell cycle proteins in brain cancer 20. Apoptosis Pathways and Chemotherapy in Brain Tumors 21. Growth Factor Signaling Pathways and Targeted Therapy 22. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas 23. PI3-kinase, Akt, mTOR and Treatment 24. Scatter Factor/HGF and C-MET in Glioblastoma 25. Targeting the sonic hedgehog pathway in brain cancers: Advances, limitations, and future directions 26. Angiogenesis and angiogenesis inhibitors in brain tumors 27. Bevacizumab and Brain Tumors 28. Histone Deacetylase Inhibitors as Therapeutic Agents
SECTION IV. CHEMOTHERAPY FOR SPECIFIC TUMORS
ADULTS 29. Historial and conventional chemotherapy approaches for high grade astrocytomas 30. The use of temozolomide for chemo-radiation and adjuvant therapy of high-grade gliomas 31. Molecular Treatment of High-Grade Glioma 32. Chemotherapy of Low-Grade Astrocytomas 33. Chemotherapy of Oligodendrogliomas 34. Chemotherapy of Primary Central Nervous System Lymphoma 35. Chemotherapy for Medulloblastoma in Adults 36. Chemotherapy of Adult Ependymoma 37. Chemotherapy for Glioneuronal Tumors 38. Medical therapy of Schwannomas 39. Chemotherapy of Pineal Parenchymal Tumors 40. Chemotherapy of Meningiomas 41. Chemotherapy of Brain Metastases
SECTION V. CHEMOTHERAPY FOR SPECIFIC TUMORS
PEDIATRICS 42. Chemotherapy of Pediatric Low-Grade Gliomas 43. Chemotherapy of Pediatric High-Grade Gliomas 44. Chemotherapy for Medulloblastoma 45. Chemotherapy of Brainstem Gliomas 46. Germ Cell Tumors 47. Chemotherapy of Ependymoma
Childhood 48. Chemotherapy for CNS Atypical Teratoid/Rhabdoid Tumor 49. Chemotherapy of Central Nervous System Primitive Neuro-Ectodermal Tumors 50. Pediatric Choroid Plexus Carcinoma: Current Management and Future Directions
SECTION VI. IMMUNOTHERAPY OF BRAIN TUMORS 51. The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade 52. Blockade of the Checkpoint Inhibitor Pathways and Activated T-cell Therapy in Brain Tumors 53. Overview of Dendritic Cell Vaccines for Brain Tumors 54. Overview of Vaccine Strategies against Epidermal Growth Factor Receptor in Brain Tumors 55. Overview of CNS Vaccines
SECTION VII. RESPONSE ASSESSMENT, QUALITY OF LIFE, AND NEUROPSYCHOLOGY 56. Issues in Response Assessment of Brain Tumor Chemotherapy 57. Pseudoprogression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation 58. Response assessment in neuro-oncology (RANO): An update 59. Immunotherapy Response Assessment in Neuro-Oncology (iRANO) 60. Quality of Life in Neuro-Oncology 61. Neuropsychology of Chemotherapy in Brain Tumor Patients
Dr. Newton is currently the Director of the Neuro-Oncology Center and CNS Oncology Program at the Florida Hospital Cancer Institute and Florida Hospital Orlando. He recently retired as a Professor of Neurology, Neurosurgery, and Oncology at the Wexner Medical Center at Ohio State University and the James Cancer Hospital, and was the holder of the Esther Dardinger Endowed Chair in Neuro-Oncology. He trained in Neuro-Oncology with Drs. Jerome Posner and William Shapiro at Memorial Sloan-Kettering Cancer Center in New York City, and since then had been in academic Neuro-Oncology for over 25 years - until his retirement. He has published more than 220 peer-reviewed articles and book chapters, and is the Chief Editor or Co-Editor of nine textbooks in the field of Neurology and Neuro-Oncology. In addition, he has been listed as a Best Doctor (Neurology) and Top Doctor for Cancer (Neuro-Oncology) for the past 18 years.